Aurora Cannabis Inc. experienced a significant decline in its stock value on Wednesday, with shares dropping over 17% following the company’s announcement of expected declines in international sales. This forecast includes markets such as the United States, where Aurora has been expanding its presence.
Despite this setback, Aurora’s stock remains up approximately 14% for the year 2025, reflecting a strong performance earlier in the year. The company released its fiscal fourth-quarter results early Wednesday, which indicated that the decline in international sales is anticipated to counterbalance the growth in medical cannabis sales within Canada.
In the latest quarter, Aurora reported revenue of 90.5 million Canadian dollars (around 66.4 million USD). This figure was bolstered by a nearly 50% year-over-year increase in medical cannabis sales, which reached 67.8 million Canadian dollars. Although the company reported a net loss of 17.2 million Canadian dollars, this was a decrease from the previous year’s loss of 20.3 million Canadian dollars, suggesting improved financial management despite the challenges in international markets.
Aurora’s outlook for the upcoming quarter suggests that global cannabis revenue will likely decline compared to the fourth quarter, primarily due to reduced international sales. The company continues to focus on expanding its medical cannabis offerings in Canada, where the market remains robust.
Investors will be closely monitoring Aurora’s performance in the coming months, particularly how it addresses the challenges in international markets while capitalizing on domestic growth opportunities.
Spanish 
English 
German 
Czech